‘Ozempic Penis’: Males Are Reporting a Surprising New GLP-1 Side Effect

A growing number of males on Reddit are claiming that GLP-1 drugs have increased their penis size. Kupicoo/Getty Images Male Reddit users are reporting what they call “Ozempic penis,” with some claiming penile growth of up to 1.5 inches. Experts say, however, that Ozempic penis is not a true side effect of GLP-1 drugs. Instead, […]

Novo Nordisk Abruptly Ends Partnership with Hims, Claiming ‘Sham Compounding’ GLP-1 Drugs – Gizmodo

Novo Nordisk Abruptly Ends Partnership with Hims, Claiming ‘Sham Compounding’ GLP-1 Drugs  Gizmodo Hims & Hers stock plunges after Novo Nordisk ends Wegovy direct sales deal  Yahoo Finance HIMS BREAKING NEWS: Hims & Hers Health, Inc. is being Investigated for Securities Fraud; Investors with Losses are Notified to Contact BFA Law  Business Wire Novo Nordisk ends collaboration with […]

CHMP Backs NVO’s Ozempic EU Label Update for Cardiovascular Indication

Novo Nordisk NVO announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that Ozempic’s (once-weekly semaglutide) label be updated to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes study. Please note that Novo Nordisk’s once-weekly subcutaneous diabetes injection, Ozempic, is […]

Hims & Hers Strengthens Its Footprint in Consumer-Driven Obesity Care

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has increasingly prioritized weight loss as a key area of growth and innovation in its healthcare platform. In recent months, the company introduced a six-month Wegovy offer priced at $549 per month for eligible new customers. This initiative was designed to improve affordability […]

Semaglutide and Tirzepatide Prescribing for Obesity

This study uses data from the US nationwide electronic health record–based Epic Cosmos Dataset to examine prescriptions for semaglutide and tirzepatide, focusing on differences across race, ethnicity, social vulnerability, and urbanicity and assess the need for strategies to promote equitable access to these therapies.